Compare Teucrium Soybean Fund (SOYB) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Teucrium Soybean Fund vs Viatris Inc — how do they compare? Teucrium Soybean Fund trades at $25.86, while Viatris Inc trades at $17.58 (market cap $19.79B). The key difference: Viatris Inc pays a 2.83% dividend while Teucrium Soybean Fund pays none. Which is the better fit depends on your goals.
| SOYB | VTRS | |
|---|---|---|
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $25.88 | $17.39 |
52-Week Low | $21.07 | $8.74 |
Market Cap | — | $19.79B |
Enterprise Value | — | $32.00B |
Dividend Yield | — | 2.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SOYB is trading at $25.88, up 1.53% today with strong technical momentum as moving averages signal bullish sentiment. The stock shows mixed oscillator readings with RSI suggesting potential overbought conditions. Recent agricultural sector news highlights potential tailwinds from China's $17 billion crop purchase commitment through 2028, which could benefit agricultural companies.
The stock presents bullish technical positioning but requires fundamental validation through upcoming earnings reports. Key risks include commodity price volatility and execution challenges. Upside potential exists if the company can capitalize on agricultural export opportunities, though investors should await financial metric updates for proper valuation assessment.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Teucrium Soybean Fund
SOYB is a commodity ETF that provides exposure to the price of soybean futures. It utilizes a laddered strategy by investing in several benchmark futures contracts to reduce the impact of roll costs and contango in the agricultural market.
Read more on SOYB →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
